Therapeutic targeting of the mitochondrial one-carbon pathway: perspectives, pitfalls, and potential
- 4 March 2021
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 40 (13) , 2339-2354
Abstract
Most of the drugs currently prescribed for cancer treatment are riddled with substantial side effects. In order to develop more effective and specific strategies to treat cancer, it is of importance to understand the biology of drug targets, particularly the newly emerging ones. A comprehensive evaluation of these targets will benefit drug development with increased likelihood for success in clinical trials. The folate-mediated one-carbon (1C) metabolism pathway has drawn renewed attention as it is often hyperactivated in cancer and inhibition of this pathway displays promise in developing anticancer treatment with fewer side effects. Here, we systematically review individual enzymes in the 1C pathway and their compartmentalization to mitochondria and cytosol. Based on these insight, we conclude that (1) except the known 1C targets (DHFR, GART, and TYMS), MTHFD2 emerges as good drug target, especially for treating hematopoietic cancers such as CLL, AML, and T-cell lymphoma; (2) SHMT2 and MTHFD1L are potential drug targets; and (3) MTHFD2L and ALDH1L2 should not be considered as drug targets. We highlight MTHFD2 as an excellent therapeutic target and SHMT2 as a complementary target based on structural/biochemical considerations and up-to-date inhibitor development, which underscores the perspectives of their therapeutic potential.Keywords
This publication has 139 references indexed in Scilit:
- Serine, glycine and one-carbon units: cancer metabolism in full circleNature Reviews Cancer, 2013
- Deletion of Mthfd1l causes embryonic lethality and neural tube and craniofacial defects in miceProceedings of the National Academy of Sciences, 2012
- Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised targetProceedings of the National Academy of Sciences, 2012
- Identification of a de novo thymidylate biosynthesis pathway in mammalian mitochondriaProceedings of the National Academy of Sciences, 2011
- Dihydrofolate Reductase Deficiency Due to a Homozygous DHFR Mutation Causes Megaloblastic Anemia and Cerebral Folate Deficiency Leading to Severe Neurologic DiseaseThe American Journal of Human Genetics, 2011
- ALDH1L2 Is the Mitochondrial Homolog of 10-Formyltetrahydrofolate DehydrogenaseJournal of Biological Chemistry, 2010
- Mitochondria as a target in treatmentEnvironmental and Molecular Mutagenesis, 2010
- Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability,Biochemistry, 2010
- Variants of human thymidylate synthase with loop 181–197 stabilized in the inactive conformationProtein Science, 2009
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)New England Journal of Medicine, 1948